Will the refusal of patent protection for Glivec® discourage future pharmaceutical innovation in India?
Dehns, St Bride's House, 10 Salisbury Square, London, EC4Y 8JD, UK. jalbutt@dehns.com.
Jodie
J
Albutt
D000970:Antineoplastic Agents; D001549:Benzamides; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D000068877:Imatinib Mesylate; D007194:India; D010330:Patents as Topic / Q000331:legislation & jurisprudence*; D010879:Piperazines; D011743:Pyrimidines
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate